On Friday, EMC Corporation (NYSE:EMC)’s shares declined -1.99% to $23.69.
WANdisco (WAND.L) a leading provider of continuous-availability software for global enterprises to meet the challenges of Big Data, recently launched a 14 day free trial version of WANdisco Fusion™ allowing users to easily evaluate the technology on their own Apache Hadoop deployments.
Large organizations use WANdisco Fusion’s patented replication technology to achieve continuous availability and performance with guaranteed data comprising across Hadoop clusters any distance apart. With its flexible architecture, WANdisco Fusion can deliver these capabilities across clusters running on the same or different versions of a single Hadoop distribution, in addition to clusters running on mixed storage platforms counting Cloudera, Hortonoperates (HDP), EMC (EMC) and MapR, completely eliminating vendor lock-in.
EMC Corporation develops, delivers, and supports information infrastructure and virtual infrastructure technologies, solutions, and services. It offers enterprise storage systems and software deployed in storage area netoperates (SAN), networked attached storage (NAS), unified storage combining NAS and SAN, object storage, and/or direct attached storage environments, in addition to provides a portfolio of backup products that support a range of enterprise application workloads.
Applied Materials, Inc. (NASDAQ:AMAT)’s shares dropped -2.35% to $15.39.
Applied Materials, Inc. declared that Robert Halliday, Senior Vice President and CFO, will take part in a question-and-answer session at the Citi Global Technology Conference in New York City on Wednesday, September 9 starting at 8:45 a.m. ET.
Applied Materials, Inc. provides manufacturing equipment, services, and software to the semiconductor, flat panel display, solar photovoltaic (PV), and related industries worldwide. The company’s Silicon Systems Group segment develops, manufactures, and sells a range of manufacturing equipment used to fabricate semiconductor chips or integrated circuits. This segment offers systems that perform primary processes used in chip fabrication, counting atomic layer deposition, chemical vapor deposition, physical vapor deposition, etch, electrochemical deposition, rapid thermal processing, ion implantation, chemical mechanical planarization, epitaxy, wet cleaning, and wafer metrology and inspection, in addition to systems that etch or inspect circuit patterns on masks used in the photolithography process. Its Applied Global Services segment provides products and services designed to enhance the performance and productivity, and reduce the environmental impact of semiconductor, display, and solar customers’ factories.
At the end of Friday’s trade, Merck & Co., Inc. NYSE:MRK)‘s shares dipped -2.01% to $51.59.
Merck (MRK), known as MSD outside the United States and Canada, recently declared that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for EMEND® (aprepitant) capsules, a substance P/neurokinin 1 (NK1) receptor antagonist. With this expanded indication, EMEND capsules are now approved for use in combination with other antiemetic agents in patients 12 years of age and older and patients less than 12 years who weigh at least 30 kg (about 66 pounds) for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) counting high-dose cisplatin, in addition to for the prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). EMEND has not been studied for treatment of established nausea and vomiting. Chronic continuous administration of EMEND is not recommended because it has not been studied, and because the drug interaction profile may change during chronic continuous use.
With this approval, EMEND is the first and only NK1 receptor antagonist to be approved for the prevention of acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV) in patients 12 to 17 years of age and patients less than 12 years who weigh at least 30 kg receiving HEC or MEC. The approval was supported by data from a pivotal Phase 3 study that showed adding EMEND to a standard regimen for prevention of CINV in HEC or MEC regimens resulted in a reduction of emetic events.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
